$30,000 of REGENERON PHARMACEUTICALS INC. lobbying was just disclosed, from Q3 of 2025, in a new Lobbying Disclosure Act filing.
This included lobbying on issues like:
"Issues related to corporate and international taxation. Issues related to OECD Pillar 2 negotiations and agreements on the taxation of global income. Issues related to IRC sections 11, 951A, 250, 162(m), and 174. (H.R. 1990, S. 1649, H.R. 1 - Sections - 70321, 70322, 70323, 70302, 70604)"
You can find more data on corporate lobbying on Quiver Quantitative.
REGN Congressional Stock Trading
Members of Congress have traded $REGN stock 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $REGN stock by members of Congress over the last 6 months:
- REPRESENTATIVE ROBERT BRESNAHAN purchased up to $15,000 on 05/15.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
REGN Hedge Fund Activity
We have seen 568 institutional investors add shares of REGN stock to their portfolio, and 657 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- FMR LLC removed 4,271,533 shares (-56.2%) from their portfolio in Q2 2025, for an estimated $2,242,554,825
- JPMORGAN CHASE & CO removed 1,718,579 shares (-30.4%) from their portfolio in Q2 2025, for an estimated $902,253,975
- DODGE & COX added 1,502,198 shares (+64.6%) to their portfolio in Q2 2025, for an estimated $788,653,950
- PRICE T ROWE ASSOCIATES INC /MD/ removed 1,408,582 shares (-64.8%) from their portfolio in Q2 2025, for an estimated $739,505,550
- CAPITAL INTERNATIONAL INVESTORS removed 823,869 shares (-20.7%) from their portfolio in Q2 2025, for an estimated $432,531,225
- AMUNDI removed 706,770 shares (-44.1%) from their portfolio in Q2 2025, for an estimated $371,054,250
- CITADEL ADVISORS LLC added 605,603 shares (+808.5%) to their portfolio in Q2 2025, for an estimated $317,941,575
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
REGN Analyst Ratings
Wall Street analysts have issued reports on $REGN in the last several months. We have seen 11 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Canaccord Genuity issued a "Buy" rating on 10/14/2025
- Citigroup issued a "Buy" rating on 10/13/2025
- Morgan Stanley issued a "Overweight" rating on 10/10/2025
- BMO Capital issued a "Outperform" rating on 08/04/2025
- JP Morgan issued a "Overweight" rating on 06/09/2025
- RBC Capital issued a "Outperform" rating on 05/27/2025
- Guggenheim issued a "Buy" rating on 05/01/2025
To track analyst ratings and price targets for REGN, check out Quiver Quantitative's $REGN forecast page.
REGN Price Targets
Multiple analysts have issued price targets for $REGN recently. We have seen 16 analysts offer price targets for $REGN in the last 6 months, with a median target of $768.5.
Here are some recent targets:
- John Newman from Canaccord Genuity set a target price of $850.0 on 10/14/2025
- Geoff Meacham from Citigroup set a target price of $660.0 on 10/13/2025
- Matthew Harrison from Morgan Stanley set a target price of $756.0 on 10/10/2025
- Akash Tewari from Jefferies set a target price of $831.0 on 08/27/2025
- William Pickering from Bernstein set a target price of $781.0 on 08/27/2025
- Srikripa Devarakonda from Truist Securities set a target price of $812.0 on 08/11/2025
- Yatin Suneja from Guggenheim set a target price of $815.0 on 08/04/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
